^(153)Sm-EDTMP的剂量-响应因素分析  

ANALYSIS OF DOSE RESPONSE FACTORS FOR 153 Sm EDTMP

作　　者：杨一峰[1] 蒋长英[1] 刁国平 王凡 顾宇参[1] 钱忠豪[1] 许峥[1] 

机构地区：[1]上海医科大学附属中山医院

出　　处：《同位素》1997年第1期7-11,共5页Journal of Isotopes

摘　　要：对２２例用１５３Ｓｍ－ＥＤＴＭＰ治疗癌性骨痛的患者进行骨照射吸收剂量分析以了解剂量－响应因素。２２例中疗效显著组１７例，无效组５例。结果表明两组间尿的累积活度、骨摄取率和单位注射剂量的骨累积活度（ｋＢｑ·ｈ／ＭＢｑ）差异均显著（Ｐ＜０．０１）。但骨的吸收活度和累积活度两组间无显著差异（Ｐ＞０．０５）。显效组红骨髓的吸收剂量为２１３．７７ｃＧｙ，无效组为１６２．０９ｃＧｙ，两组无显著差异（Ｐ＞０．０５），均在安全剂量范围。结果提示对骨的相对剂量分布的分析有助于进一步阐明剂量－响应关系。To interpret the clinical response phenomena, an analysis of bone radiation absorbed dose is performed on 22 patients using 153 Sm EDTMP therapy to painful bone metastases. Two groups, significant pain relief 17 patients and no response 5 patients, are divided. The remarkable differences ( P <0.01) between groups are the cumulative urine activity, skeletal uptake rate and cumulative skeletal activity every MBq. No significant difference ( P >0.05), either in skeletal activity or total cumulative skeletal activity is detected. The radiation absorbed dose to red marrow averages 213.77 cGy (relief group) and 162.09 cGy (no response group) respectively ( P >0.05), both are in the safe dose range. Analysis of bone relative dose distribution may help to reveal the relationship of the dose response.

关 键 词：剂量-响应因素 癌性骨痛 放射疗法 钐153 EDTMP 

分 类 号：R730.55[医药卫生—肿瘤] R815[医药卫生—临床医学]